Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well that's why I'm working on improving Omni's board. data can be more compiled than it is. an issue on our board due to back and forth jabs pertaining to relevant company information is realistically diluting user experience especially on our boards ibox. my section will be kept neat clean and lean with hyper focused info that uses links to access abundance through google docs. I hope to be an example for future ibox's right now my section is so young and lacking and i cant wait to have it complete. im actively learning al lthe tools in the box as i go so its only gunna get better from here.
solutions are solutions and omni is working on pain management solutions.
RELIVATROL
say hello to speedtrader folks interested in CE stocks
higher fee's but with a long term horizon the short term cost is mitigated with fruitful investing.
$50 per trade
$120 annual trading fee if you don't trade x15 times a month.
and other restrictions butt there pretty mediocre.
hence why the pharmacy website was redone and not deleted because a launch will come after creditors take wishful pot shots..
there is abundance on the other side we just aren't privvy to it yet. we will be though. in due time.
take a close look at LX Retail group thats the wall to the other side thats why merger language exists in the filings cause this is all intended to clean the books of malecon and leave creditors wishing the would of could of should of...
we would of already have done this by 99% of OTC standards. most businesses fail within 3 years on the contrary on the back end this company is innovating products like relivatrol with real trials underwway even with lawsuits flying over creditors being short sighted and lacking vision.
andrey is 1099 for a reason hes taking on water for the team while they build on the other side of the wall before the wall comes down. hes merely a pawn he isn't the king in this.
hes a shareholder like you and me the only difference hes got ownership through holding companies so they cant touch the real fruits of the labor.
gotta get past the lawsuits then we flying.
edited: are we able/allowed to add youtube videos to the ibox intro of an ihub board?
here is how i am attempting to insert it as is right now:
example https://www.youtube.com /watch?v=[yt ]fFGTxZWCI3w[ /yt ]
" rel="nofollow" target="_blank">https://www.youtube.com/watch?v=
well contrary to popular belief these securities provide tremendous value when investors operate with maximum due diligence.
I'm out to prove this thesis. Through my various due diligence methods. keep an eye on OMHE as a targeted example of my thesis fruitioning over time.
for those curious on speed trader costs for people interested in holding securities. they do allow CE entry
~deposit required=2,500
~$120 annual inactivity fee=$30quarterly "penalized for not trading 15x a month".
~$55 per trade.
all this said for value investors looking to go long in securities an alternative to these brokers and the increasing BIG DAD approach by the government is to pursue what is known as a DSP direct sale plan into the company.
and yet opportunity lurks in choppy waters
it's a good thing this restriction is not really applicable to those who can freely move from broker to broker acting in there individual best interest.
why not? say more. leave us cliff hanging sheesh.
latest omnihealth, inc court case records 2020-2021+:
on going civil debt case
could firer oleg be our next CEO?
https://www.bloomberg.com/profile/person/6621042
hes named in the on going suit regarding omni notes.
will update with court records when I obtain/if I obtain them sent a public records request just moments ago via us mail.
Andrey's drowning in legal battles with creditors:
https://onlineservices.miami-dadeclerk.com/officialrecords/StandardSearch.aspx
I can count em on my fingers! lmfao so that's good.
Besides he definitely knows I'm kinda his reporter lmfao I keep you guys so fresh on updates it's cray-cray lightning fast.
I'm sure Andrey would love to communicate and has been quietly dying to reveal the progress.
watching thanks.
from speedtrader:
Illiquid Securities Policy – All clients of our firm in aggregate cannot trade in excess of 10% of the previous 20 business day average trading volume of any stock on any day regardless of the stock’s price. In addition, for stocks trading below $1 per share, clients cannot ever trade more than 25% of the current day’s trading volume. There also cannot at anytime ever be more than 5,000,000 shares of any one stock settling during any 3 business day settlement period for our entire firm. If a client trades in excess of these restrictions, then their accounts will be subject to fees and interest charges and possible buy in or sell out of the violating position during the 3-day settlement period of those trades. There will be a $300 fee for any trade that is in violation of this policy. The interest charges will then be assessed on an illiquidity requirement imposed on the clearing firm, which could be many times the value of the trade. The interest rates charged to clients who violate these restrictions will be a minimum overnight rate of 15% of the illiquidity requirement. These are only guideline amounts and lower trading volumes can also trigger illiquid charges, which will be passed through as well. Repeated violations of this policy will result in the account being closed.
watching thanks.
omnis study funded by 100B company:
Conclusion: The MCII is a relevant measure for
studies of patients with OA because it considers
patient perspectives on clinical improvements. In
this analysis, this criterion was applied to data
from a previously published clinical trial of
patients with OA of the hand for the first time.
Most patients treated with DSG 1% achieved clinically meaningful relief within 1 week that was
sustained for ≥8 weeks. Despite placebo response
rates of 44% to 52%, a significantly higher percentage of patients had MCII responses with
DSG 1%, providing evidence for the efficacy of
DSG.
Acknowledgement/Funding Source: This study
was funded by GlaxoSmithKline Consumer
Healthcare.
GlaxoSmithKline Consumer Healthcare investor in relivatrol study
this implies they a are 100B company funding omnihealths research and an investor in omnihealths future.
References
1. Hochberg MC, et al. American College of Rheumatology 2012
recommendations for the use of nonpharmacologic and
pharmacologic therapies in osteoarthritis of the hand, hip, and
knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474.
2. Bellamy N, et al. Development of multinational definitions of
minimal clinically important improvement and patient acceptable
symptomatic state in osteoarthritis. Arthritis Care Res (Hoboken).
2015 Jul;67(7):972-980.
*C20—Pain Management
A Novel Approach in the Management
of Post-Episiotomy Pain
Yisroel Grabie, OMS II1
; Zara Jamil, OMS II1
;
Joseph Schwob, OMS II1
; Boris Petrikovsky, MD,
PhD1
; Arkady Uryash, MD, PhD1
1
New York Institute of Technology College of
Osteopathic Medicine; 2
Garden OB/GYN; 3
Mount
Sinai Medical Center
Statement of Significance: The first tenet of
osteopathic medicine states: “The body is a unit
the person is a unit of body, mind, and spirit.”
Given that childbirth is a traumatic event for the
mother, in addition to the fact that postpartum
depression rates are considerable, it seems valuable to explore novel pain management resources
using the osteopathic holistic philosophy for the
treatment of postepisiotomy pain. It is our belief
that in treating a mother’s perineal pain, we may
also improve her overall mind and spirit enhancing her wellbeing.
Methods: This pilot study was conducted in an
outpatient obstetrics clinic located in Miami, F.L.
involving postpartum women between the ages of
18-39 years of age, who underwent vaginal delivery with episiotomy. Spray bottles with the investigational product were distributed to the patients
to manage their pain freely without regulation. A
survey to assess postepisiotomy pain using the
Visual Analog Scale (VAS) was administered to
the patients. Pain attenuation, time to pain attenuation, and quality of pain were measured
Data Analysis: Analysis of this preliminary study
indicates that Relivatrol© significantly reduced
postepisiotomy pain. We are currently in the
process of replicating this study on a larger scale
in order to address limitations inherent to the
study’s design.
Results: The cohort consisted of 25 postpartum
women. Of note, there were 5 women who did
not respond to the treatment. The investigational
product attenuated pain by an average of 3.2
scale units. Additionally, in a subgroup analysis
of the “responders”, pain was attenuated by 4.0
scale units. Pre-administration pain quality was
reported as sharp (n=12), achy (n=6), and dull
(n=5). In the participants who responded to treatment, the average time to analgesia was reported
to be 9.25 Average pain ratings after treatment
were compared with average pain ratings before
treatment using a unidirectional paired sample t
test (df=24). The average pain ratings for the
entire cohort (including non-responders) after
administration of Relivatrol© were significantly
lower than average pain rating prior to administration t(24)=7.41, P<.0001.
Conclusion: We concluded that Relivatrol© significantly decreases postepisiotomy pain. Since
this pilot study had multiple limitations, we developed a protocol for a larger investigation involving a greater number of participants, a control
ABSTRACTS
e116 The Journal of the American Osteopathic Association November 2019 | Vol 119 | No. 12
arm, pharmacokinetic parameters, and an analysis
of quality of life impact.
Acknowledgment/Funding Source: None
reported.
References
1. Friedman AM, Ananth CV, Prendergast E, D’Alton ME, Wright
JD. Variation in and Factors Associated With Use of Episiotomy.
Jama. 2015;313(2):197. doi:10.1001/jama.2014.14774.
2. Tsuchiya H. Anesthetic Agents of Plant Origin: A Review of
Phytochemicals with Anesthetic Activity. Molecules. 2017;22
(8):1369. doi:10.3390/molecules22081369.
3. DiGiovanna EL, Schiowitz S, Dowling DJ. An Osteopathic
Approach to Diagnosis and Treatment. Philadelphia, PA:
Lippincott Williams and Wilkins; 2005.
4. Hieger MA, Afeld JL, Cumpston KL, Wills BK. Topical
Benzocaine and Methemoglobinemia American Journal of
Therapeutics. 2017; 24(5):e596-e598.American journal of
therapeutics. 2017;24:e596.
in omnis case:
1. omni is hiding its website IP this is why we can't access omnihealth.md but we can see its there.
we see that maleconpharmacy.com has been approved by management as ready to launch. I saw awhile ago they acquired a cyber security firms help for whatever reason. i presume to help masks domains so they could launch them test them without people like me seeing the changes.
we can also see that other known company sites are also under the same security as omnihealth.md
Me going to see Andrey:
L2 omni has a lot of market makers does this mean anything of some kind of relevance to experienced traders? its hosting more than it typically does i see.
Who,what,when,where,why positive and negatively. lots of things to learn here past,present and future for omnihealth inc.
It was not a shipping Issue it was a production issue for the type of bottle required is how it was explained to me.
They also indicated a desire to wait until covid was over with to launch. So this new variant could delay it even more but they could decide to launch whenever however they see fit.
and yes I saw a quote on ian Cassels babe I really liked " be impatient daily and be patient for decades holding. or something to that extent and all we can do is hold everything is out of our hands without more reputable people willing to pressure the company we can't achieve anything.
we have options theyve just never been used before in OTC markets.
Like a derivative suit and audits of the books and more by recruiting 5% of the active float etc.
In the future I hope to have the resources to do these things to put the power in shareholder hands right now the available tools for a level playing field don't exist for the average shareholder
currently trying to get a job at a cannabis shop In tallassee, FL i hope to talk to the owner about omnis products.
shumer introduced federal legalization legislation this week in the senate. could it be a/the catalyst management has been waiting for?
according to my convo with andrew they can/could sell relivatrol without the cannabis infusion but i wonder how much was affected by FDA when the were selling it on amazon and on there websites. and at the time of convo they were having issues sources the types of bottles they required. so again not sure how much has changed since those convos are awhile ago now.
if it is I can't wait to find out how and why to learn from it.
Is OMHE reconning coming Sept? tik tac tok.
Pretty good volume today given the inability of anybody to acquire
Grabbed this on my stockpile account awhile ago.
sugar goes good with more than lemons.
Martin Luther king Jr faught and won over time a utmost important cause and gave his life as a result. I see Omni as not only a investment but a launch pad for a better future.
well if I'm Andrey I stay quiet and hide lmfao. but... I'm looking into derivative suits. Its not really common in OTC's could even be yet another attempt at a first. I'm interested in bringing the power to investors who are serious about smaller companies to embolden the shareholders to hold these smaller companies like Omni to higher standards. I believe in active and reactive shareholders who want to drive a better more responsible market. and ultimately I may end up working with passionate people creating the required tools to empower shareholders.
Let's say worst case scenario is applied we always learn we always grow. so in this likely out come I want to know how and where the company went down hill I have some very early knowledge about this. I also have some late stage knowledge but in the middle something plausibly caused catastrophe and I do desire to know if that event whatever it is or was caused what we see today or if this was a long thought out process to spin off and reward the dump of vitacig and wash away the pharmacy debt.
I'll provide a more detailed break down of how I believe it could of fallen apart if it has or does.
Again as always innocent until proven guilty and as always it's possible a merger and product news flows at any moment it's so far in either direction it's crazy. I'd aken the company to powerball odds but prior when we weren't this uninformed about company events our odds of success based on due diligence did indeed look promising so again gotta wait gotta see gotta learn from this either way.
almost everyone assumes it.
we've seen relivatrol video produced in 2020 in a lab setting.
Interesting possibility: rentable biolabs. https://cic.com/miami-laboratory
news article of own labs:
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/omni-health-announces-opening-biotech-100000648.html
Yes definitely, how far out remains to be seen. it's going to pop the stock like a rocket kinda like gwso did.
Exciting times ahead. good thing omnis are the best products for pain management.